Friday, January 27, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

Mechanism of Action for Drugs Against Arenaviruses

by Global Biodefense Staff
July 21, 2014
USAMRIID Arenavirus Mechanism of Action

The U.S. Army Medical Research Acquisition Activity (USAMRAA) is seeking firms capable of providing research services to develop mechanisms of action for FDA-approved drugs against Arenaviruses.

The contract will support ongoing work on biothreat countermeasures by the Virology Division within the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID).

USAMRIID has screened a library containing over 3200 FDA-approved drugs to identify ones that inhibit infections by multiple pathogenic viruses. Those tested include six hemorrhagic fever viruses (Ebolavirus, Marburgvirus, Dengue Virus, West Nile Virus, Lassa Fever Virus, and Rift Valley Fever Virus) and four alphaviruses (Western, Eastern, and Venezuelan encephalitis viruses and Chikungunya virus), representing 5 families of enveloped RNA viruses (filo-, flavi-, arena-, bunya-, and alphaviruses).

From this effort, they have identified approximately 140 Highly Active Anti-viral Lead Therapeutics (HALLT) compounds that block infection by members of two or more virus families. Understanding the Mechanism of Action (MOA) would improve understanding as to how these compounds may be inhibiting infection and at which stage of virus replication to develop more effective therapeutics.

Previous efforts against filoviruses have focused on specifically designed Ebolavirus (EBOV) virus like particles (VLPs) that recapitulate the filamentous shape and entry properties of authentic EBOV, through the incorporation of the EBOV glycoprotein (GP). Just like other enveloped viruses, it is the GP that dictates all aspects of virus entry. Additionally, these VLPs incorporate two engineered forms of EBOV VP40, one tagged with β-lactamase and one tagged with mCherry. VP40 directs the assembly of EBOV VLPs, similar to authentic virus. The β-lactamase VP40 acts a reported when the VLPs have fused with a cellular membrane and have entered into the cytoplasma; whereas, the mCherry VP40 provides a fluorescent tag for visualizing the VLPs during cellular entry.

The proposed work for this solicitation is to develop a similar pseudoviron assay for arenaviruses and identify the mechanism of action of several compounds identified in the authentic virus screens completed by USAMRIID.

USAMRAA anticipates awarding a single contract for one base year plus four option years for these services.

Further details are available under Solicitation Number: W81XWH-14-R-0082. The response deadline is July 31, 2014.

Tags: ArenavirusEbolaLassa FeverRFI

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC